“The Sprague Dawley rat, Beagle dog and Cynomolgus monkey were the main species used for toxicological assessment of lurbinectedin.”
✓ VerifiedFDA multi-discipline review, p. 28Source ↗
Why that species
Monkey chosen as non-rodent because its metabolism was more similar to human than other non-rodents
“Despite using dogs in the initial 4-week toxicology studies, the Applicant utilized the monkey in the 13-week non-rodent toxicology study due to metabolic data suggesting that monkey metabolism was more similar to human than other tested non-rodent species.”
✓ VerifiedFDA multi-discipline review, p. 28Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“Intravenous administration of PM01183 at the dose of 0.125 mg/kg every 3 weeks for 8-cycles was not tolerated by Cynomolgus monkeys”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Species: general tox
Rat, beagle dog and cynomolgus monkey
“The Sprague Dawley rat, Beagle dog and Cynomolgus monkey were the main species used for toxicological assessment of lurbinectedin.”
✓ VerifiedFDA multi-discipline review, p. 28Source ↗
Species: DART
Rat only (preliminary single-dose EFD study); no fertility or pre/postnatal studies
“Given its mechanism of action as a genotoxic agent targeting rapidly dividing cells, FDA would not generally request an embryofetal development study, however, the Applicant did conduct a preliminary single dose, single-dose level embryo-fetal development study in rats.”
✓ VerifiedFDA multi-discipline review, p. 29Source ↗
Species: carcinogenicity
Not conducted (advanced cancer patient population)
“The Applicant did not conduct carcinogenicity studies based on the proposed patient population.”
✓ VerifiedFDA multi-discipline review, p. 29Source ↗
Surrogate used in
No surrogate used; lurbinectedin tested directly
“The Sprague Dawley rat, Beagle dog and Cynomolgus monkey were the main species used for toxicological assessment of lurbinectedin.”
✓ VerifiedFDA multi-discipline review, p. 28Source ↗